Literature DB >> 2211826

Identification of a multifunctional, cell-binding peptide sequence from the a1(NC1) of type IV collagen.

E C Tsilibary1, L A Reger, A M Vogel, G G Koliakos, S S Anderson, A S Charonis, J N Alegre, L T Furcht.   

Abstract

We have previously identified three distinctive amino acid sequences from type IV collagen which specifically bound to heparin and also inhibited the binding of heparin to intact type IV collagen. One of these chemically synthesized domains, peptide Hep-I, has the sequence TAGSCLRKFSTM and originates from the a1(noncollagenous [NC1]) chain of type IV collagen (Koliakos, G. G., K. K. Koliakos, L. T. Furcht, L. A. Reger, and E. C. Tsilibary. 1989. J. Biol. Chem. 264:2313-2323). We describe in this report that this same peptide also bound to intact type IV collagen in solid-phase assays, in a dose-dependent and specific manner. Interactions between peptide Hep-I and type IV collagen in solution resulted in inhibition of the assembly process of this basement membrane glycoprotein. Therefore, peptide Hep-I should represent a major recognition site in type IV collagen when this protein polymerizes to form a network. In addition, solid phase-immobilized peptide Hep-I was able to promote the adhesion and spreading of bovine aortic endothelial cells. When present in solution, peptide Hep-I competed for the binding of these cells to type IV collagen- and NC1 domain-coated substrata in a dose-dependent manner. Furthermore, radiolabeled peptide Hep-I in solution also bound to endothelial cells in a dose-dependent and specific manner. The binding of radiolabeled Hep-I to endothelial cells could be inhibited by an excess of unlabeled peptide. Finally, in the presence of heparin or chondroitin/dermatan sulfate glycosaminoglycan side chains, the binding of endothelial cells to peptide Hep-I and NC1 domain-coated substrates was also inhibited. We conclude that peptide Hep-I should have a number of functions. The role of this type IV collagen-derived sequence in such diverse phenomena as self-association, heparin binding and cell binding and adhesion makes Hep-I a crucial domain involved in the determination of basement membrane ultrastructure and cellular interactions with type IV collagen-containing matrices.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2211826      PMCID: PMC2116235          DOI: 10.1083/jcb.111.4.1583

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  37 in total

1.  A simple ultraviolet spectrophotometric method for the determination of protein.

Authors:  W J WADDELL
Journal:  J Lab Clin Med       Date:  1956-08

2.  cDNA clones coding for the pro-alpha1(IV) chain of human type IV procollagen reveal an unusual homology of amino acid sequences in two halves of the carboxyl-terminal domain.

Authors:  T Pihlajaniemi; K Tryggvason; J C Myers; M Kurkinen; R Lebo; M C Cheung; D J Prockop; C D Boyd
Journal:  J Biol Chem       Date:  1985-06-25       Impact factor: 5.157

3.  Amino acid sequence of the non-collagenous globular domain (NC1) of the alpha 1(IV) chain of basement membrane collagen as derived from complementary DNA.

Authors:  I Oberbäumer; M Laurent; U Schwarz; Y Sakurai; Y Yamada; G Vogeli; T Voss; B Siebold; R W Glanville; K Kühn
Journal:  Eur J Biochem       Date:  1985-03-01

4.  cDNA and protein sequence of the NC1 domain of the alpha 2-chain of collagen IV and its comparison with alpha 1(IV).

Authors:  U Schwarz-Magdolen; I Oberbäumer; K Kühn
Journal:  FEBS Lett       Date:  1986-11-24       Impact factor: 4.124

5.  Heparin type IV collagen interactions: equilibrium binding and inhibition of type IV collagen self-assembly.

Authors:  E C Tsilibary; G G Koliakos; A S Charonis; A M Vogel; L A Reger; L T Furcht
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

Review 6.  Focal adhesions and cell-matrix interactions.

Authors:  A Woods; J R Couchman
Journal:  Coll Relat Res       Date:  1988-03

7.  Self-assembly of basement membrane collagen.

Authors:  P D Yurchenco; H Furthmayr
Journal:  Biochemistry       Date:  1984-04-10       Impact factor: 3.162

Review 8.  Nonenzymatic glycosylation and the pathogenesis of diabetic complications.

Authors:  M Brownlee; H Vlassara; A Cerami
Journal:  Ann Intern Med       Date:  1984-10       Impact factor: 25.391

9.  Structure of a cDNA for the pro alpha 2 chain of human type I procollagen. Comparison with chick cDNA for pro alpha 2(I) identifies structurally conserved features of the protein and the gene.

Authors:  M P Bernard; J C Myers; M L Chu; F Ramirez; E F Eikenberry; D J Prockop
Journal:  Biochemistry       Date:  1983-03-01       Impact factor: 3.162

10.  Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin.

Authors:  D M Haverstick; J F Cowan; K M Yamada; S A Santoro
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

View more
  14 in total

Review 1.  New functional roles for non-collagenous domains of basement membrane collagens.

Authors:  Nathalie Ortega; Zena Werb
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

Review 2.  Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes.

Authors:  J Des Parkin; James D San Antonio; Vadim Pedchenko; Billy Hudson; Shane T Jensen; Judy Savige
Journal:  Hum Mutat       Date:  2011-02       Impact factor: 4.878

Review 3.  Type IV collagen-derived angiogenesis inhibitors.

Authors:  Thomas M Mundel; Raghu Kalluri
Journal:  Microvasc Res       Date:  2007-05-25       Impact factor: 3.514

4.  Extracellular matrix-derived peptides and myocardial repair.

Authors:  Shirley S Mihardja; Jiashing Yu; Randall J Lee
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

5.  Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation.

Authors:  M Zeisberg; G Bonner; Y Maeshima; P Colorado; G A Müller; F Strutz; R Kalluri
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

6.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin.

Authors:  Yuki Hamano; Michael Zeisberg; Hikaru Sugimoto; Julie C Lively; Yohei Maeshima; Changqing Yang; Richard O Hynes; Zena Werb; Akulapalli Sudhakar; Raghu Kalluri
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

7.  Targeted in vivo extracellular matrix formation promotes neovascularization in a rodent model of myocardial infarction.

Authors:  Shirley S Mihardja; Dongwei Gao; Richard E Sievers; Qizhi Fang; Jinjin Feng; Jianming Wang; Henry F Vanbrocklin; James W Larrick; Manley Huang; Michael Dae; Randall J Lee
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

Review 8.  Mammalian collagen IV.

Authors:  Jamshid Khoshnoodi; Vadim Pedchenko; Billy G Hudson
Journal:  Microsc Res Tech       Date:  2008-05       Impact factor: 2.769

Review 9.  Extracellular matrix in pancreatic islets: relevance to scaffold design and transplantation.

Authors:  John C Stendahl; Dixon B Kaufman; Samuel I Stupp
Journal:  Cell Transplant       Date:  2009       Impact factor: 4.064

10.  Signaling mechanisms of endogenous angiogenesis inhibitors derived from type IV collagen.

Authors:  Akulapalli Sudhakar; Chandra S Boosani
Journal:  Gene Regul Syst Bio       Date:  2007-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.